BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37225860)

  • 1. Phase II trial of delta-tocotrienol in neoadjuvant breast cancer with evaluation of treatment response using ctDNA.
    Kjær IM; Kahns S; Timm S; Andersen RF; Madsen JS; Jakobsen EH; Tabor TP; Jakobsen A; Bechmann T
    Sci Rep; 2023 May; 13(1):8419. PubMed ID: 37225860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Methylated Circulating Tumor DNA With Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
    Takahashi H; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Clin Breast Cancer; 2017 Feb; 17(1):61-69.e3. PubMed ID: 27395416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Riva F; Bidard FC; Houy A; Saliou A; Madic J; Rampanou A; Hego C; Milder M; Cottu P; Sablin MP; Vincent-Salomon A; Lantz O; Stern MH; Proudhon C; Pierga JY
    Clin Chem; 2017 Mar; 63(3):691-699. PubMed ID: 28073896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
    Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
    Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
    Zhou Q; Gampenrieder SP; Frantal S; Rinnerthaler G; Singer CF; Egle D; Pfeiler G; Bartsch R; Wette V; Pichler A; Petru E; Dubsky PC; Bago-Horvath Z; Fesl C; Rudas M; Ståhlberg A; Graf R; Weber S; Dandachi N; Filipits M; Gnant M; Balic M; Heitzer E
    Clin Cancer Res; 2022 Feb; 28(4):697-707. PubMed ID: 34862246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Magbanua MJM; Swigart LB; Wu HT; Hirst GL; Yau C; Wolf DM; Tin A; Salari R; Shchegrova S; Pawar H; Delson AL; DeMichele A; Liu MC; Chien AJ; Tripathy D; Asare S; Lin CJ; Billings P; Aleshin A; Sethi H; Louie M; Zimmermann B; Esserman LJ; van 't Veer LJ
    Ann Oncol; 2021 Feb; 32(2):229-239. PubMed ID: 33232761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.
    Rothé F; Silva MJ; Venet D; Campbell C; Bradburry I; Rouas G; de Azambuja E; Maetens M; Fumagalli D; Rodrik-Outmezguine V; Di Cosimo S; Rosa D; Chia S; Wardley A; Ueno T; Janni W; Huober J; Baselga J; Piccart M; Loi S; Sotiriou C; Dawson SJ; Ignatiadis M
    Clin Cancer Res; 2019 Jun; 25(12):3581-3588. PubMed ID: 30862692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delta tocotrienol in recurrent ovarian cancer. A phase II trial.
    Thomsen CB; Andersen RF; Steffensen KD; Adimi P; Jakobsen A
    Pharmacol Res; 2019 Mar; 141():392-396. PubMed ID: 30639384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying Circulating Tumor DNA Mutations Associated with Neoadjuvant Chemotherapy Efficacy in Local Advanced Breast Cancer.
    Wei B; Shan Y; Du Z; Yin C; Zhang Q; Lin H; Zhang G; Song D; Zuo H
    Appl Biochem Biotechnol; 2022 Sep; 194(9):3961-3973. PubMed ID: 35579744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
    Hrebien S; Citi V; Garcia-Murillas I; Cutts R; Fenwick K; Kozarewa I; McEwen R; Ratnayake J; Maudsley R; Carr TH; de Bruin EC; Schiavon G; Oliveira M; Turner N
    Ann Oncol; 2019 Jun; 30(6):945-952. PubMed ID: 30860573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.
    Cailleux F; Agostinetto E; Lambertini M; Rothé F; Wu HT; Balcioglu M; Kalashnikova E; Vincent D; Viglietti G; Gombos A; Papagiannis A; Veys I; Awada A; Sethi H; Aleshin A; Larsimont D; Sotiriou C; Venet D; Ignatiadis M
    JCO Precis Oncol; 2022 Sep; 6():e2200148. PubMed ID: 36170624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.